PEP-Therapy

About:

Innovative peptides as targeted therapies for oncology

Top Investors: Bpifrance, Seventure Partners, Les Business Angels des Grandes Écoles, Anaxago, i&i Prague

Description:

PEP-Therapy is a biotechnology company developing first-in-class peptides as targeted therapies for severe diseases, with an initial focus on cancer. PEP-Therapy develops Cell Penetrating and Interfering Peptides (CP&IP) for the intracellular delivery of targeted therapies. These active compounds penetrate cells and block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.

Total Funding Amount:

7.85M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Évry, Ile-de-France, France

Founded Date:

2014-01-02

Contact Email:

hello.pep(AT)pep-therapy.com

Founders:

Antoine Prestat

Number of Employees:

1-10

Last Funding Date:

2021-07-19

IPO Status:

Private

Industries: